Development of Opsonic Mouse Monoclonal Antibodies against Multidrug-Resistant Enterococci
Autor: | Ermioni Kalfopoulou, Suzana Malić, Roberto Adamo, Karmela Miklić, Tihana Lenac Rovis, Johannes Huebner, Stipan Jonjić, Diana Laverde, Felipe Romero-Saavedra, Filippo Carboni |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2019 |
Předmět: |
0301 basic medicine
medicine.drug_class Enterococcus faecium 030106 microbiology Immunology SagA Biology Monoclonal antibody Microbiology Enterococcus faecalis opsonic Mice 03 medical and health sciences Antigen Polysaccharides medicine Animals Bacterial Capsules opsonophagocytic assay Antigens Bacterial hybridoma technology BIOMEDICINE AND HEALTHCARE. Basic Medical Sciences Antibodies Monoclonal Drug Resistance Microbial Opsonin Proteins biology.organism_classification capsular polysaccharide 3. Good health Multiple drug resistance DHG diheteroglycan monoclonal antibodies 030104 developmental biology Infectious Diseases Microbial Immunity and Vaccines biology.protein Hybridoma technology Parasitology Immunotherapy Bacterial antigen Antibody BIOMEDICINA I ZDRAVSTVO. Temeljne medicinske znanosti |
Zdroj: | Infection and Immunity Volume 87 Issue 9 |
ISSN: | 0019-9567 1098-5522 |
DOI: | 10.1128/iai.00276-19 |
Popis: | Multidrug-resistant enterococci are major causes of hospital-acquired infections. Immunotherapy with monoclonal antibodies (MAbs) targeting bacterial antigens would be a valuable treatment option in this setting. Here, we describe the development of two MAbs through hybridoma technology that target antigens from the most clinically relevant enterococcal species. Multidrug-resistant enterococci are major causes of hospital-acquired infections. Immunotherapy with monoclonal antibodies (MAbs) targeting bacterial antigens would be a valuable treatment option in this setting. Here, we describe the development of two MAbs through hybridoma technology that target antigens from the most clinically relevant enterococcal species. Diheteroglycan (DHG), a well-characterized capsular polysaccharide of Enterococcus faecalis, and the secreted antigen A (SagA), an immunogenic protein from Enterococcus faecium, are both immunogens that have been proven to raise opsonic and cross-reactive antibodies against enterococcal strains. For this purpose, a conjugated form of the native DHG with SagA was used to raise the antibodies in mice, while enzyme-linked immunosorbent assay and opsonophagocytic assay were combined in the selection process of hybridoma cells producing immunoreactive and opsonic antibodies targeting the selected antigens. From this process, two highly specific IgG1(κ) MAbs were obtained, one against the polysaccharide (DHG.01) and one against the protein (SagA.01). Both MAbs exhibited good opsonic killing against the target bacterial strains: DHG.01 showed 90% killing against E. faecalis type 2, and SagA.01 showed 40% killing against E. faecium 11231/6. In addition, both MAbs showed cross-reactivity toward other E. faecalis and E. faecium strains. The sequences from the variable regions of the heavy and light chains were reconstructed in expression vectors, and the activity of the MAbs upon expression in eukaryotic cells was confirmed with the same immunological assays. In summary, we identified two opsonic MAbs against enterococci which could be used for therapeutic or prophylactic approaches against enterococcal infections. |
Databáze: | OpenAIRE |
Externí odkaz: |